Fig. 13

Oral administration of dasatinib daily for 2 weeks significantly decreases the LPS-induced increment of Iba-1 and GFAP immunoreactivity in wild-type mice. a, c Wild-type mice were injected with dasatinib (20 mg/kg, p.o.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, p.o.) daily for 2 weeks, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, immunohistochemistry was conducted with an anti-Iba-1 antibody. b Quantification of the data in a (cortex: con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). d, e Quantification of the data in c (hippocampus: con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). f Wild-type mice were injected with dasatinib (20 mg/kg, p.o.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, p.o.) daily for 2 weeks, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, immunohistochemistry was conducted with an anti-GFAP antibody. g, h Quantification of the data in f (hippocampus: con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). One-way ANOVA with Tukey’s post hoc test was used to analyze significant differences. *p < 0.05, **p < 0.01, ***p < 0.001